Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Current gene therapy using viral vectors for chronic pain

Guedon, JMG and Wu, S and Zheng, X and Churchill, CC and Glorioso, JC and Liu, CH and Liu, S and Vulchanova, L and Bekker, A and Tao, YX and Kinchington, PR and Goins, WF and Fairbanks, CA and Hao, S (2015) Current gene therapy using viral vectors for chronic pain. Molecular Pain, 11 (1). ISSN 1744-8069

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (2MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© Guedon et al.; licensee BioMed Central. The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Guedon, JMG
Wu, S
Zheng, X
Churchill, CC
Glorioso, JCglorioso@pitt.eduGLORIOSO
Liu, CH
Liu, S
Vulchanova, L
Bekker, A
Tao, YX
Kinchington, PRkinch@pitt.eduKINCH
Goins, WFgoins@pitt.eduGOINS
Fairbanks, CA
Hao, S
Date: 13 May 2015
Date Type: Publication
Journal or Publication Title: Molecular Pain
Volume: 11
Number: 1
DOI or Unique Handle: 10.1186/s12990-015-0018-1
Schools and Programs: School of Medicine > Microbiology and Molecular Genetics
School of Medicine > Molecular Virology and Microbiology
School of Medicine > Ophthalmology
Refereed: Yes
ISSN: 1744-8069
Date Deposited: 16 Aug 2016 14:40
Last Modified: 04 Feb 2019 23:55
URI: http://d-scholarship.pitt.edu/id/eprint/29276

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item